Shots:
- The UK’s MHRA has approved Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) with HFO-1234ze(E), a next-generation, near-zero global warming potential (GWP) propellant for treating COPD in adults; regulatory review is ongoing in EU, China & other regions
- Approval was based on a next-generation propellant clinical development program assessing Trixeo + HFO-1234ze(E) vs Trixeo + HFA-134a, which showed bioequivalence between the two
- Additionally, AstraZeneca plans to transition its pMDI portfolio to near-zero GWP propellants by 2030 as part of its Ambition Zero Carbon strategy, starting with Trixeo in the UK in the coming mos.
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca Reports P-III (POTOMAC) Trial Findings of Imfinzi Regimen for High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click Here for Full Press Release
